Literature DB >> 20665663

The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation.

Xiaodong Li1, Meghan E McGee-Lawrence, Matthew Decker, Jennifer J Westendorf.   

Abstract

Ewing's sarcomas are highly aggressive round cell tumors of bone and soft tissues that afflict children and young adults. The majority of these tumors harbor the t(11;22) translocation and express the fusion protein EWS-FLI. Modern molecular profiling experiments indicate that Ewing's tumors originate from mesenchymal precursors in young individuals. EWS-FLI alters the morphology of mesenchymal cells and prevents lineage specification; however, the molecular mechanisms for differentiation arrest are unclear. We recently showed that EWS-FLI binds Runx2, a master regulator of osteoblast differentiation. In this report, we demonstrate that FLI sequences within EWS-FLI are responsible for interactions with Runx2. EWS-FLI blocks the expression of osteoblastic genes in a multipotent progenitor cell line that requires Runx2 to integrate bone morphogenic protein (Bmp)2 signaling while increasing proliferation and altering cell morphology. These results demonstrate that EWS-FLI blocks the ability of Runx2 to induce osteoblast specification of a mesenchymal progenitor cell. Disrupting interactions between Runx2 and EWS-FLI1 may promote differentiation of the tumor cell.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665663      PMCID: PMC3877924          DOI: 10.1002/jcb.22782

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  42 in total

1.  DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets.

Authors:  Martin S Staege; Christoph Hutter; Ingo Neumann; Sabine Foja; Uwe E Hattenhorst; Gesine Hansen; Danny Afar; Stefan E G Burdach
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

Review 2.  TLS, EWS and TAF15: a model for transcriptional integration of gene expression.

Authors:  Warren J Law; Kendra L Cann; Geoffrey G Hicks
Journal:  Brief Funct Genomic Proteomic       Date:  2006-02-23

Review 3.  Context matters: the hen or egg problem in Ewing's sarcoma.

Authors:  Heinrich Kovar
Journal:  Semin Cancer Biol       Date:  2005-06       Impact factor: 15.707

4.  Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells.

Authors:  Nicolò Riggi; Luisa Cironi; Paolo Provero; Mario-Luca Suvà; Konstantinos Kaloulis; Carlos Garcia-Echeverria; Francesco Hoffmann; Andreas Trumpp; Ivan Stamenkovic
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 5.  Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP).

Authors:  Jinhui Liao; Laurie K McCauley
Journal:  Cancer Metastasis Rev       Date:  2006-12       Impact factor: 9.264

6.  RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region.

Authors:  Marcie Fowler; Erkut Borazanci; Laura McGhee; Shannon Walls Pylant; B Jill Williams; Jonathan Glass; J Nathan Davis; Shari Meyers
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

7.  Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal.

Authors:  Amjad Javed; Jong-Sup Bae; Faiza Afzal; Soraya Gutierrez; Jitesh Pratap; Sayyed K Zaidi; Yang Lou; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  J Biol Chem       Date:  2008-01-18       Impact factor: 5.157

8.  Mesenchymal stem cell features of Ewing tumors.

Authors:  Franck Tirode; Karine Laud-Duval; Alexandre Prieur; Bruno Delorme; Pierre Charbord; Olivier Delattre
Journal:  Cancer Cell       Date:  2007-05       Impact factor: 31.743

9.  Ets factors and a newly identified polymorphism regulate Fli1 promoter activity in lymphocytes.

Authors:  Tamara K Nowling; Jennifer Dziadyk Fulton; Katherine Chike-Harris; Gary S Gilkeson
Journal:  Mol Immunol       Date:  2007-07-02       Impact factor: 4.407

10.  A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature.

Authors:  Jeffrey D Hancock; Stephen L Lessnick
Journal:  Cell Cycle       Date:  2007-10-30       Impact factor: 4.534

View more
  26 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

Review 2.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

3.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

4.  Atypical growth on MRI in a case of Ewing's sarcoma despite lower SUV on PET.

Authors:  Zachary Sanford; Stanford Israelsen; Rajesh Sehgal; Felix H Cheung
Journal:  Skeletal Radiol       Date:  2013-12-19       Impact factor: 2.199

5.  Biomechanical regulation of drug sensitivity in an engineered model of human tumor.

Authors:  A Marturano-Kruik; A Villasante; K Yaeger; S R Ambati; A Chramiec; M T Raimondi; G Vunjak-Novakovic
Journal:  Biomaterials       Date:  2017-10-10       Impact factor: 12.479

6.  RUNX3 facilitates growth of Ewing sarcoma cells.

Authors:  Krista L Bledsoe; Meghan E McGee-Lawrence; Emily T Camilleri; Xiaoke Wang; Scott M Riester; Andre J van Wijnen; Andre M Oliveira; Jennifer J Westendorf
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

7.  Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

Authors:  Savita Sankar; Emily R Theisen; Jared Bearss; Timothy Mulvihill; Laura M Hoffman; Venkataswamy Sorna; Mary C Beckerle; Sunil Sharma; Stephen L Lessnick
Journal:  Clin Cancer Res       Date:  2014-06-24       Impact factor: 12.531

8.  Clinicopathological implications of GNAS in Ewing sarcoma.

Authors:  Byeong-Joo Noh; Ji-Youn Sung; Youn Wha Kim; Eduardo Santini Araujo; Ricardo Karam Kalil; Woon-Won Jung; Hyun-Sook Kim; Yong-Koo Park
Journal:  Oncol Lett       Date:  2016-05-05       Impact factor: 2.967

9.  Allosteric interference in oncogenic FLI1 and ERG transactions by mithramycins.

Authors:  Caixia Hou; Abhisek Mandal; Jürgen Rohr; Oleg V Tsodikov
Journal:  Structure       Date:  2020-12-03       Impact factor: 5.006

Review 10.  Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.

Authors:  Balaji Ramachandran; Thangarajan Rajkumar; Gopal Gopisetty
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.